Gisbert, JP;
Molina-Infante, J;
Amador, J;
Bermejo, F;
Bujanda, L;
Calvet, X;
Castro-Fernández, M;
Cuadrado-Lavín, A;
Elizalde, JI;
Gene, E;
Gomollón, F;
Lanas, Á;
Martín de Argila, C;
Mearin, F;
Montoro, M;
Pérez-Aisa, Á;
Pérez-Trallero, E;
McNicholl, AG.
Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus meetings on H.pylori infection had been performed in Spain (the last in 2012). The changes in the treatment schemes, and the increasing available ev...
Anti-Bacterial Agents/therapeutic use,
Proton Pump Inhibitors/therapeutic use,
Bismuth/therapeutic use,
Algorithms,
Delphi Technique,
Drug Therapy, Combination,
Gastritis/complications,
Helicobacter Infections,
Helicobacter pylori,
Probiotics,
Proton Pump Inhibitors,
Recurrence,
Salvage Therapy,
Stomach Neoplasms,
Stomach Ulcer,
Treatment Failure,
Gastritis/drug therapy,
Helicobacter Infections/drug therapy,
Helicobacter pylori/drug effects
Macle, L;
Cairns, J;
Leblanc, K;
Tsang, T;
Skanes, A;
Cox, JL;
Healey, JS;
Bell, A;
Pilote, L;
Andrade, JG;
Mitchell, LB;
Atzema, C;
Gladstone, D;
Sharma, M;
Verma, S;
Connolly, S;
Dorian, P;
Parkash, R;
Talajic, M;
Nattel, S;
Verma, A.
The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the management of antithrombotic therapy for AF pa...
Anticoagulants,
Cardiotonic Agents,
Platelet Aggregation Inhibitors,
Digoxin,
Magnesium,
Acute Coronary Syndrome/therapy,
Algorithms,
Anticoagulants/therapeutic use,
Atrial Appendage/surgery,
Atrial Fibrillation,
Cardiac Pacing, Artificial,
Cardiotonic Agents/adverse effects,
Catheter Ablation,
Cardiotonic Agents/administration & dosage,
Atrial Fibrillation/therapy,
Atrial Fibrillation/complications,
Hemorrhage/chemically induced,
Hemorrhage/prevention & control,
Magnesium/therapeutic use,
Percutaneous Coronary Intervention,
Platelet Aggregation Inhibitors/therapeutic use,
Postoperative Complications/prevention & control,
ST Elevation Myocardial Infarction/therapy,
Stroke/prevention & control,
Coronary Artery Disease/complications,
Digoxin/administration & dosage,
Digoxin/adverse effects,
Drug Therapy, Combination,
Factor Xa Inhibitors/therapeutic use,
Fibrinolytic Agents/therapeutic use,
Factor Xa Inhibitors
Singh, J. A;
Saag, K. G;
Bridges Junior, S. L;
Akl, E. A;
Bannuru, R. R;
Sullivan, M. C;
Vaysbrot, E;
McNaughton, C;
Osani, M;
Shmerling, R. H;
Curtis, J. R;
Furst, D. E;
Parks, D;
Kavanaugh, A;
O'Dell, J;
King, C;
Leong, A;
Matteson, E. L;
Schousboe, J. T;
Drevlow, B;
Ginsberg, S;
Grober, J;
St Clair, E. W;
Tindall, E;
Miller, A. S;
McAlindon, T.
OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Eval...
Rationale for the guidelines: Since the publication of the WHO Guidelines for the management of sexually transmitted infections in 2003, changes in the epidemiology of STIs and advancements in prevention, diagnosis and treatment necessitate changes in STI management. These guidelines provide updated trea...
Rationale for the guidelines: Since the publication of the WHO Guidelines for the management of sexually transmitted infections in 2003, changes in the epidemiology of STIs and advancements in prevention, diagnosis and treatment necessitate changes in STI management. There is an urgent need to update tre...
Neisseria gonorrhoeae,
Gonorrhea/drug therapy,
Drug Resistance, Microbial,
Cefixime/administration & dosage,
Spectinomycin/administration & dosage,
Ceftriaxone/administration & dosage,
Gentamicins/administration & dosage,
Kanamycin/administration & dosage,
Tetracycline/administration & dosage,
Erythromycin/administration & dosage,
Povidone-Iodine/administration & dosage,
Silver Nitrate/administration & dosage,
Chloramphenicol/therapeutic use,
Anti-Bacterial Agents/administration & dosage,
Drug Therapy, Combination
The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority...